Drug, across the briefings
Retifanlimab across 12 cancers
Retifanlimab appears in 12 of the briefings; its FDA label names 2 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Anal cancer | label names disease | approved on PDCD1 | 3 | 1 |
| Merkel cell carcinoma | label names disease | approved on PDCD1 | 5 | 3 |
| Basal cell carcinoma | approved on PDCD1 | — | — | |
| Cervical cancer | approved on PDCD1 | — | — | |
| Cutaneous squamous cell carcinoma | approved on PDCD1 | — | — | |
| Esophageal cancer | approved on PDCD1 | 1 | 1 | |
| Head and neck cancer | approved on PDCD1 | 5 | 1 | |
| Hodgkin lymphoma | approved on PDCD1 | — | — | |
| Melanoma | approved on PDCD1 | 3 | 0 | |
| Mesothelioma | approved on PDCD1 | 1 | 0 | |
| Nasopharyngeal carcinoma | approved on PDCD1 | — | — | |
| Vulvar cancer | approved on PDCD1 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.